University of Kansas Medical Center

Illuminate Announces an Enterprise Solution to the Follow-Up of Actionable Incidental Findings

Retrieved on: 
화요일, 11월 7, 2023
RSNA, Intelligence, Discovery, Health, Software, Illuminate, Incidental Findings, Medical Education Number, Radiological Society of North America, University, North Hall, University of Kansas Medical Center, Patient, Medical imaging, Radiology

OVERLAND PARK, Kan., Nov. 7, 2023 /PRNewswire/ -- Softek Illuminate, Inc., a provider of enterprise follow-up management and discovery software, announces the ability of their Discovery360™ services to offload the follow-up responsibility from radiology and enable the entire health system to efficiently participate in the management of patients' Actionable Incidental Findings (AIFs).

Key Points: 
  • OVERLAND PARK, Kan., Nov. 7, 2023 /PRNewswire/ -- Softek Illuminate, Inc. , a provider of enterprise follow-up management and discovery software, announces the ability of their Discovery360™ services to offload the follow-up responsibility from radiology and enable the entire health system to efficiently participate in the management of patients' Actionable Incidental Findings (AIFs).
  • Discovery360 helps improve radiologist productivity by ensuring the broader care team sees all AIFs, whether or not they include an explicit follow-up recommendation.
  • This provides radiology with the assurance that any AIF in their clinical report is seen and acted upon.
  • In addition, Discovery360 provides a single enterprise IT follow-up solution that eliminates departmental staffing challenges associated with identifying, tracking, and managing patients with AIFs.

Springbok Analytics announces partnership with Friends of FSH Research

Retrieved on: 
수요일, 10월 18, 2023
Science, 3D, Research, Facial muscles, MRI, Facioscapulohumeral muscular dystrophy, Health, University of Rochester Medical Center, Biomarker, Kennedy Krieger Institute, Johns Hopkins, FSHD, CO, MSK, Seattle Children's, Organization, Inflammation, Edema, HIV disease progression rates, Drug development, Disease, Partnership, DRS, Magnetic resonance imaging, University, University of Kansas Medical Center, NIH, Patient, Hospital, Springbok, Pharmaceutical industry, Medical imaging, Friends

Friends of FSH Research ("Friends") is fully committed to transparent, reproducible, and transformative science that will inspire hope for people living with FSHD.

Key Points: 
  • Friends of FSH Research ("Friends") is fully committed to transparent, reproducible, and transformative science that will inspire hope for people living with FSHD.
  • FSHD is a highly complex and progressive muscle wasting disease which causes weakening and loss of skeletal muscle in adults and children.
  • "We started Friends 20 years ago with the singular mission of stimulating and funding FSHD research in order to find a treatment or a cure.
  • Springbok Analytics reveals never-before-seen data to improve health, performance, treatment monitoring and MSK function.

Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Retrieved on: 
수요일, 8월 16, 2023
Graft-versus-host disease, System, University, Acute radiation syndrome, Nature, ARS, Marketing, Cellular, University of Kansas Health System, HCT, Pluri Inc., Cell, PLUR, Cytopenia, Regeneration, Patient, University of Kansas Medical Center, TASE, Blood, Vein graft failure, NIAID, Placentalia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry

As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.

Key Points: 
  • As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.
  • Low levels of blood cells (cytopenia) post-HCT can persist despite adequate engraftment of donor cells.
  • Pluri’s PLX-R18 cells secrete a large array of hematopoietic factors which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood.
  • As a groundbreaking, first-in-class solution, PLX-R18’s capacity to augment hematopoietic system recovery and effectively manage diverse cytopenia holds immense promise.”

OCU Health Care Inc. Launches Groundbreaking Patient Technology Solution with Kansas Medical Center

Retrieved on: 
목요일, 8월 3, 2023
Hardware, Health Technology, Telemedicine, Virtual Medicine, Consumer Electronics, Other Health, Technology, Practice Management, Managed Care, General Health, Hospitals, Wearables, Mobile Technology, Other Technology, Biotechnology, Software, Health, KMC, Partnership, Education, Patient, Overalls, Research, OHC, VR, National Association Medical Staff Services, Agency for Healthcare Research and Quality, Hospital, Agency, University of Kansas Medical Center, Virtual reality, AHRQ, Nursing

Ocu Health Care (OHC) Inc., is thrilled to announce the launch of its groundbreaking platform aimed at revolutionizing healthcare, reducing costs, and delivering better patient outcomes through tailored educational programs prior to discharge.

Key Points: 
  • Ocu Health Care (OHC) Inc., is thrilled to announce the launch of its groundbreaking platform aimed at revolutionizing healthcare, reducing costs, and delivering better patient outcomes through tailored educational programs prior to discharge.
  • OHC is partnering with Kansas Medical Center, in its effort to provide a select group of patients with technology products that deliver education with a low-stress experience through VR headsets.
  • “We’re collecting insightful feedback and patient data to tap into innovative ways to continue refining this technology and introduce Ocu Health Care as a valuable resource for patients and medical professionals nationwide,” Darkazanli said.
  • To learn more about Ocu Health Care, please visit us at www.ocuhealthcare.com or reach out to Ammar Darkazanli at [email protected] regarding investment opportunities.

Exxat Announces Recipients of the 2023 Student Scholarship Program

Retrieved on: 
수요일, 8월 2, 2023
Southern California University of Health Sciences, University, Care, Evidence-based practice, Employment, Occupational therapy, Doctor of Philosophy, University of Kansas Medical Center, Student, Diversity, Outline of health sciences, Washington University School of Medicine, Nursing, SMART Defense Scholarship Program, George Washington University School of Nursing, Inclusion, Faculty Scholarly Productivity Index, Scholarly method, Health, Jane and Robert Cizik School of Nursing, Veterinary medicine

WARREN, N.J., Aug. 2, 2023 /PRNewswire/ -- Exxat, a leading provider of clinical and experiential education management solutions, today announced the achievements of 16 students through the Exxat Student Scholarship program. These scholarships are awarded across four categories: Scholarly Productivity, Diversity and Inclusion, Leadership, and Care for Underserved Communities, spotlighting the contributions of these students to the future of healthcare.

Key Points: 
  • WARREN, N.J., Aug. 2, 2023 /PRNewswire/ -- Exxat , a leading provider of clinical and experiential education management solutions, today announced the achievements of 16 students through the Exxat Student Scholarship program.
  • "Each year, through the Exxat Scholarship Program, we have the privilege of encountering remarkable young individuals who exhibit a desire to make a positive impact on the world and in their respective fields," said Aarti Vaishnav, Founder and CEO of Exxat.
  • The 2023-24 academic year recipients are:
    Abriana Berkowitz: Washington University School of Medicine in St Louis, Physical Therapy
    Information and the online application for the 2024-2025 Exxat Student Scholarship will be available in March 2024.
  • To learn more about Exxat's Scholarship Program, visit here .

Dr. Thomas Hunt Appointed as Lee Health’s Vice President and Chief Physician Executive of Musculoskeletal Services

Retrieved on: 
월요일, 7월 17, 2023
Bachelor of Science in Nursing, Perioperative, University, Stanford University, Elective surgery, Arizona Cardinals, Health, Spine, University of Kansas Health System, Rehabilitation, Baylor St. Luke's Medical Center, Vanderbilt University School of Medicine, Disorder, Hospital of the University of Pennsylvania, National Association Medical Staff Services, Doctorate, Houston Texans, Physician, NBA, Injury, University of Kansas Medical Center, Joint, Hospital, American College, Hand, CommonSpirit Health, Safety, Nursing, Medicine

He is an experienced physician leader, orthopedic educator and clinical innovator, having published numerous articles, book chapters, textbooks, and delivered countless lectures and symposia.

Key Points: 
  • He is an experienced physician leader, orthopedic educator and clinical innovator, having published numerous articles, book chapters, textbooks, and delivered countless lectures and symposia.
  • Dr. Hunt also designed unique surgical implants used today for wrist fracture fixation as well as protocols permitting precise, remote and perioperative care.
  • His most recent clinical leadership positions include chief of the musculoskeletal service line at Baylor St. Luke’s Medical Center in Houston and chief physician executive for CommonSpirit Health’s Texas Division orthopedic service line.
  • We know he will be a huge asset to Southwest Florida,” said Dr. Iahn Gonsenhauser, Lee Health’s chief medical officer.

Comparative Analysis Concludes Posterior Approach to SI Joint Fusion is as Effective as the Lateral Approach

Retrieved on: 
수요일, 6월 7, 2023
SI, Sacroiliac joint dysfunction, Anesthesiology, LinQ, UCLA Health, MD, Patient, University, University of Kansas Medical Center, Sacroiliac joint, Trauma, Synovial joint, Safety, 3D printing, Dentistry

TAMPA, Fla., June 7, 2023 /PRNewswire/ -- The results of a comparative biomechanical analysis of the posterior sacroiliac (SI) joint fusion to the traditional lateral approach show that a posterior SI joint fusion with LinQ, a novel implant developed by Tampa-based medical device company, PainTEQ, has stabilization results comparable to the lateral approach when put through the same tests.

Key Points: 
  • TAMPA, Fla., June 7, 2023 /PRNewswire/ -- The results of a comparative biomechanical analysis of the posterior sacroiliac (SI) joint fusion to the traditional lateral approach show that a posterior SI joint fusion with LinQ, a novel implant developed by Tampa-based medical device company, PainTEQ , has stabilization results comparable to the lateral approach when put through the same tests.
  • "In a very well-designed, comparative cadaveric, biomechanical study, the authors have demonstrated that LinQ posterior sacroiliac fusion results in superior stabilization of the sacroiliac joint compared to lateral approach instrumentation.
  • This analysis is the first study ever to compare the newer, minimally invasive posterior approach to the lateral method.
  • The study concluded that posterior fusion has similar performance in stabilizing the SI joint during flexion-extension motions and superior performance in stabilizing the SI joint during lateral bending and axial rotation motions compared to the lateral approach (See Figures 1-3).

Waters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System

Retrieved on: 
월요일, 6월 5, 2023
WAT, American Society for Mass Spectrometry, Food, University, Senior, Signal-to-noise ratio, PFAS, ASMS, Workflow, Atmosphere, Mass spectrometry, DESI, Brain, Lung, University of Kansas Medical Center, Soil, Laboratory, Paracetamol, Fomepizole, Water, Liver, Waters Corporation, Piaggio Xevo, Society, NYSE, Nanwang water division system, Software, Medical imaging, Pharmaceutical industry

HOUSTON, June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today launched the industry's first targeted imaging mass spectrometer based on its Xevo™ TQ Absolute tandem quadrupole mass spectrometer, the most sensitive and compact mass spectrometer in its class. The new instrument combines the Waters™ DESI XS source with the Xevo TQ Absolute system and is five times more sensitive and five times faster than discovery-based imaging systems at precisely determining whether a particular small molecule drug product – and how much of it - reaches its intended target, such as a brain, liver, or lung, in a test subject.

Key Points: 
  • Waters combines the enhanced desorption electrospray ionization (DESI) source with the Xevo TQ Absolute tandem quadrupole mass spectrometer to enable faster and more sensitive targeted pre-clinical MS imaging experiments.
  • Waters adds DESI XS source to its Xevo TQ Absolute mass spectrometer for fast and sensitive targeted MS imaging.
  • "Customers have successfully applied the Xevo TQ Absolute system to solve a host of problems including PFAS testing at parts-per-quadrillion levels," said Jon Pratt, Senior Vice President, Waters Division.
  • "The DESI XS source features a high-performance sprayer and that makes the DESI source robust so we can work much more efficiently," said Dr. Akakpo.

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

Retrieved on: 
목요일, 6월 1, 2023
Research, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, Molecule, Arrowhead, Idiopathic pulmonary fibrosis, Asthma, Research and development, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, Serum, CTA, Targeted molecular therapy for neuroblastoma, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, Hepatocyte, University of Kansas Medical Center, Small RNA, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, Liver, RNA interference, ASCVD, Adipose tissue, Moyamoya disease, R, Goldberg, ALS, Gene, Medical device, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.
  • ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “In 2017 we had optimized the TRiM™ platform for hepatocyte delivery, but we had yet to advance any candidates into clinical studies.
  • (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and Ira Goldberg, M.D.

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

Retrieved on: 
화요일, 4월 25, 2023
Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecule, Arrowhead, Interim, Critical care, RAGE, Asthma, University, Folate targeting, University of Kansas Health System, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Trial of the century, Arrowhead Pharmaceuticals, Patient, University of Kansas Medical Center, RNA interference, Research, Safety, Pharmaceutical industry

These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.

Key Points: 
  • These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.
  • Matthias Salathe, M.D., Professor, Pulmonary, Critical Care and Sleep Medicine, and Vice Chancellor for Research at the University of Kansas Medical Center, said: “These interim ARO-RAGE Phase 1/2 data are highly encouraging.
  • Unmet need continues to exist for many patients with severe asthma who suffer from persistent symptoms and exacerbations, despite current therapies.
  • The high level of target gene knockdown, the long duration of effect, and the promising safety and tolerability results are all very encouraging signs for our growing pipeline of RNAi therapeutic candidates that leverage this same platform.